カテゴリー： FactMR, 世界, 医療/バイオ

脂質異常症治療薬の世界市場2023年-2033年：予測・動向・分析・競争状況

◆英語タイトル：Dyslipidemia Therapeutics Market By Type (Low-density Lipoproteins (LDL), Triglycerides), By Drug Class (Statins, Non-Statins, Combination Drugs), By Distribution Channel (Hospitals Pharmacies, Drug Stores, Retail Stores, Mail Order Pharmacies), and Region - Global Market Insights 2023 to 2033

FactMRが発行した調査報告書（FACT23MA035）◆商品コード：FACT23MA035
◆発行会社（リサーチ会社）：FactMR
◆発行日：2023年4月6日
◆ページ数：約170
◆レポート形式：英語 / PDF
◆納品方法：Eメール
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧、印刷不可）USD4,500 ⇒換算￥684,000見積依頼/購入/質問フォーム
Global Site License（同一拠点内共有可）USD8,500 ⇒換算￥1,292,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Fact.MR社の本市場調査資料では、世界の脂質異常症治療薬市場を徹底的に調査・分析し、予測期間中（2023年〜2033年）の動向を展望しています。本書は、エグゼクティブサマリー、イントロダクション、市場動向、種類別（低密度リポタンパク質（LDL）、トリグリセリド）分析、治療薬クラス別（スタチン、非スタチン、合剤）分析、流通チャネル別（病院薬局、ドラッグストア、小売店、通販薬局）分析、地域別（北米、中南米、ヨーロッパ、ロシア、アジア太平洋、中国、日本、中東・アフリカ）分析、競争分析、企業情報、仮定、調査手法など、以下の構成でまとめています。なお、主な市場参入企業として、AstraZeneca、Kowa Pharmaceuticals America, Inc.、Merck & Co.などの情報を含んでいます。
・エグゼクティブサマリー
・イントロダクション
・市場動向
・世界の脂質異常症治療薬市場規模：種類別
- 低密度リポタンパク質（LDL）の市場規模
- トリグリセリドの市場規模
・世界の脂質異常症治療薬市場規模：治療薬クラス別
- スタチン治療薬における市場規模
- 非スタチン治療薬における市場規模
- 合剤における市場規模
・世界の脂質異常症治療薬市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- ドラッグストアチャネルの市場規模
- 小売店チャネルの市場規模
- 通販薬局チャネルの市場規模
・世界の脂質異常症治療薬市場規模：地域別
- 北米の脂質異常症治療薬市場規模
- 中南米の脂質異常症治療薬市場規模
- ヨーロッパの脂質異常症治療薬市場規模
- ロシアの脂質異常症治療薬市場規模
- アジア太平洋の脂質異常症治療薬市場規模
- 中国の脂質異常症治療薬市場規模
- 日本の脂質異常症治療薬市場規模
- 中東・アフリカの脂質異常症治療薬市場規模
・競争分析
・企業情報
・仮定
・調査手法

本資料には、各企業の製品ポートフォリオや主要戦略、包括的なSWOT分析などの要素を含む企業情報を含んでいます。企業のプレゼンスは、すべての主要プレーヤーについてマッピングされ、マトリックスを通して提供されます。これにより、読者に実用的な洞察を提示し、熟考して市場の状況を提供し、脂質異常症治療薬における競争レベルを推測するのに役立ちます。

DYSLIPIDEMIA THERAPEUTICS Market – Scope of Report

A recent study by Fact.MR on the DYSLIPIDEMIA THERAPEUTICS market offers a 10-year forecast for 2023 to 2033. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players associated with offering Dyslipidemia Therapeutics.
The study also provides the dynamics responsible for influencing the future status of the DYSLIPIDEMIA THERAPEUTICS market over the forecast period. A detailed assessment of value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report.

A list of prominent companies operating in the DYSLIPIDEMIA THERAPEUTICS market, along with their product portfolios, key strategies and SWOT analysis, enhances the reliability of this comprehensive research study.

Report Summary

The study offers comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales of DYSLIPIDEMIA THERAPEUTICS across the globe.
A comprehensive estimate on the market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of DYSLIPIDEMIA THERAPEUTICS during the forecast period. Price point comparison by region with global average price is also considered in the study.

Analysis on Market Size Evaluation

The market has been analyzed for each segment in terms of value (US$ Mn).
Estimates at global and regional levels for DYSLIPIDEMIA THERAPEUTICS are available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent market segments, along with market attractiveness evaluation, has been incorporated in the report. Furthermore, absolute dollar opportunity analysis of all the segments adds prominence to the report.
Absolute dollar opportunity plays a crucial role in assessing the level of opportunity that a manufacturer/distributor can look to achieve, along with identifying potential resources, considering the sales and distribution perspective in the global DYSLIPIDEMIA THERAPEUTICS market.

Inspected Assessment on Regional Segments

Key sections have been elaborated in the report, which have helped deliver projections on regional markets. These chapters include regional macros (political, economic, and business environment outlook), which are expected to have a momentous influence on the growth of the DYSLIPIDEMIA THERAPEUTICS market during the forecast period.
Country-specific valuation on demand for DYSLIPIDEMIA THERAPEUTICS has been offered for each region, along with market scope estimates and forecasts, price index, and impact analysis of the dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.
Detailed breakup in terms of value & volume for emerging countries has also been included in the report.

In-depth Analysis on Competition

The report sheds light on leading manufacturers of XYZ, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in offering DYSLIPIDEMIA THERAPEUTICS has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, which include essentials such as product portfolios and key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting the market status, and predicting the competition level in the DYSLIPIDEMIA THERAPEUTICS domain.

❖ レポートの目次 ❖

1. Executive Summary

    1.1. Market Overview

    1.2. Market Analysis

    1.3. FACT.MR Analysis and Recommendations

    1.4. Wheel of Fortune

2. Market Introduction

    2.1. Market Introduction

    2.2. Market Definition

    2.3. Market Taxonomy

3. Market Dynamics

    3.1. Growth Drivers and Impact Analysis

    3.2. Industry Challenges and Impact Analysis

    3.3. Industry trends and Impact analysis

    3.4. Opportunity Assessment in Market

    3.5. Macro – Economic Factors influencing demand

    3.6. PESTEL Analysis

4. Global Market Analysis and Forecast

    4.1. Global Market Outlook

        4.1.1. Market Value (US$ Mn) Forecast and Analysis

        4.1.2. Price Index and Price Point Assessment, by key Products

        4.1.3. Regional Demand Assessment

            4.1.3.1. Market Value Share by Region

    4.2. Global Market Analysis by Type

        4.2.1. Low-density Lipoproteins (LDL)

        4.2.2. Triglycerides

    4.3. Market Analysis by Drug Class

        4.3.1. Statins

        4.3.2. Non-Statins

            4.3.2.1. PCSK9 inhibitors

            4.3.2.2. Cholesterol absorption inhibitors

            4.3.2.3. Bile Acid resins

            4.3.2.4. Fibrate

            4.3.2.5. Others

        4.3.3. Combinations Drugs

    4.4. Market Analysis by Distribution Channel

        4.4.1. Hospitals Pharmacies

        4.4.2. Drug Stores

        4.4.3. Retail Stores

        4.4.4. Mail Order Pharmacies

5. North America Market Analysis

    5.1. Introduction

        5.1.1. North America Business Outlook

        5.1.2. North America Market Outlook

    5.2. North America Market Outlook

        5.2.1. Market Value (US$ Mn) Forecast and Analysis

        5.2.2. Country Wise Demand Assessment

            5.2.2.1. US Market Value Share

            5.2.2.2. Canada Market Value Share

    5.3. North America Market Analysis by Product Type

        5.3.1. Value (US$ Mn) Forecast by Type

        5.3.2. Y-o-Y Growth Comparison by Type

    5.4. North America Market Analysis by Drug Class

        5.4.1. Value (US$ Mn) Forecast by Drug Class

        5.4.2. Y-o-Y Growth Comparison by Drug Class

    5.5. North America Market Analysis by Distribution Channel

        5.5.1. Value (US$ Mn) Forecast by Distribution Channel

        5.5.2. Y-o-Y Growth Comparison by Distribution Channel

    5.6. Market Attractiveness Analysis

6. Latin America Market Analysis

    6.1. Introduction

        6.1.1. Latin America Business Outlook

        6.1.2. Latin America Market Outlook

    6.2. Latin America Market Outlook

        6.2.1. Value (US$ Mn) Forecast and Analysis

        6.2.2. Country Wise Demand Assessment

            6.2.2.1. Brazil Market Value Share

            6.2.2.2. Mexico Market Value Share

            6.2.2.3. Rest of LA Market Value Share

    6.3. Latin America Market Analysis by Type

        6.3.1. Value (US$ Mn) Forecast by Type

        6.3.2. Y-o-Y Growth Comparison by Type

    6.4. Latin America Market Analysis by Drug Class

        6.4.1. Value (US$ Mn) Forecast by Drug Class

        6.4.2. Y-o-Y Growth Comparison by Drug Class

    6.5. Latin America Market Analysis by Distribution Channel

        6.5.1. Value (US$ Mn) Forecast by Distribution Channel

        6.5.2. Y-o-Y Growth Comparison by Distribution Channel

    6.6. Market Attractiveness Analysis

7. Europe Market Analysis

    7.1. Introduction

        7.1.1. Europe Business Outlook

        7.1.2. Europe Market Outlook

    7.2. Europe Market Outlook

        7.2.1. Value (US$ Mn) Forecast and Analysis

        7.2.2. Country Wise Demand Assessment

            7.2.2.1. Germany Market Value Share

            7.2.2.2. UK Market Value Share

            7.2.2.3. France Market Value Share

            7.2.2.4. Spain Market Value Share

            7.2.2.5. Italy Market Value Share

            7.2.2.6. Rest of Europe Market Value Share

    7.3. Europe Market Analysis by Type

        7.3.1. Value (US$ Mn) Forecast by Type

        7.3.2. Y-o-Y Growth Comparison by Type

    7.4. Europe Market Analysis by Drug Class

        7.4.1. Value (US$ Mn) Forecast by Drug Class

        7.4.2. Y-o-Y Growth Comparison by Drug Class

    7.5. Europe Market Analysis by Distribution Channel

        7.5.1. Value (US$ Mn) Forecast by Distribution Channel

        7.5.2. Y-o-Y Growth Comparison by Distribution Channel

    7.6. Market Attractiveness Analysis

8. CIS & Russia Market Analysis

    8.1. Introduction

        8.1.1. CIS & Russia. Business Outlook

        8.1.2. CIS & Russia Market Outlook

    8.2. CIS & Russia Market Outlook

        8.2.1. Market Value (US$ Mn) Forecast and Analysis

    8.3. CIS & Russia Market Analysis by Type

        8.3.1. Value (US$ Mn) Forecast by Type

        8.3.2. Y-o-Y Growth Comparison by Type

    8.4. CIS & Russia Market Analysis by Drug Class

        8.4.1. Value (US$ Mn) Forecast by Drug Class

        8.4.2. Y-o-Y Growth Comparison by Drug Class

    8.5. CIS & Russia Market Analysis by Distribution Channel

        8.5.1. Value (US$ Mn) Forecast by Distribution Channel

        8.5.2. Y-o-Y Growth Comparison by Distribution Channel

    8.6. Market Attractiveness Analysis

9. Asia Pacific Excluding Japan & China Market Analysis

    9.1. Introduction

        9.1.1. Asia Pacific Excluding Japan & China Business Outlook

        9.1.2. Asia Pacific Excluding Japan & China Market Outlook

    9.2. Asia Pacific Excluding Japan & China Market Outlook

        9.2.1. Value (US$ Mn), Forecast and Analysis

        9.2.2. Country Wise Demand Assessment

            9.2.2.1. India Market Value Share

            9.2.2.2. Australia & New Zealand Market Value Share

            9.2.2.3. Rest of APEJC Market Value Share

    9.3. Asia Pacific Excluding Japan & China Market Analysis by Type

        9.3.1. Value (US$ Mn) Forecast by Type

        9.3.2. Y-o-Y Growth Comparison by Type

    9.4. Asia Pacific Excluding Japan & China Market Analysis by Drug Class

        9.4.1. Value (US$ Mn) Forecast by Drug Class

        9.4.2. Y-o-Y Growth Comparison by Drug Class

    9.5. Asia Pacific Excluding Japan & China Market Analysis by Distribution Channel

        9.5.1. Value (US$ Mn) Forecast by Distribution Channel

        9.5.2. Y-o-Y Growth Comparison by Distribution Channel

    9.6. Market Attractiveness Analysis

10. China Market Analysis

    10.1. Introduction

        10.1.1. China Business Outlook

        10.1.2. China Market Outlook

    10.2. China Market Outlook

        10.2.1. Market Value (US$ Mn) Forecast and Analysis

    10.3. China Market Analysis by Type

        10.3.1. Value (US$ Mn) Forecast by Type

        10.3.2. Y-o-Y Growth Comparison by Type

    10.4. China Market Analysis by Drug Class

        10.4.1. Value (US$ Mn) Forecast by Drug Class

        10.4.2. Y-o-Y Growth Comparison by Drug Class

    10.5. China Market Analysis by Distribution Channel

        10.5.1. Value (US$ Mn) Forecast by Distribution Channel

        10.5.2. Y-o-Y Growth Comparison by Distribution Channel

    10.6. Market Attractiveness Analysis

11. Japan Market Analysis

    11.1. Introduction

        11.1.1. Japan Business Outlook

        11.1.2. Japan Market Outlook

    11.2. Japan Market Outlook

        11.2.1. Market Value (US$ Mn) Forecast and Analysis

    11.3. Japan Market Analysis by Type

        11.3.1. Value (US$ Mn) Forecast by Type

        11.3.2. Y-o-Y Growth Comparison by Type

    11.4. Japan Market Analysis by Drug Class

        11.4.1. Value (US$ Mn) Forecast by Drug Class

        11.4.2. Y-o-Y Growth Comparison by Drug Class

    11.5. Japan Market Analysis by Distribution Channel

        11.5.1. Value (US$ Mn) Forecast by Distribution Channel

        11.5.2. Y-o-Y Growth Comparison by Distribution Channel

    11.6. Market Attractiveness Analysis

12. MEA Market Analysis

    12.1. Introduction

        12.1.1. MEA Business Outlook

        12.1.2. MEA Market Outlook

    12.2. MEA Market Outlook

        12.2.1. Value (US$ Mn) Forecast and Analysis

        12.2.2. Country Wise Demand Assessment

            12.2.2.1. GCC Countries Market Value Share

            12.2.2.2. South Africa Market Value Share

            12.2.2.3. Rest of MEA Market Value Share

    12.3. MEA Market Analysis by Type

        12.3.1. Value (US$ Mn) Forecast by Type

        12.3.2. Y-o-Y Growth Comparison by Type

    12.4. MEA Market Analysis by Drug Class

        12.4.1. Value (US$ Mn) Forecast by Drug Class

        12.4.2. Y-o-Y Growth Comparison by Drug Class

    12.5. MEA Market Analysis by Distribution Channel

        12.5.1. Value (US$ Mn) Forecast by Distribution Channel

        12.5.2. Y-o-Y Growth Comparison by Distribution Channel

    12.6. Market Attractiveness Analysis

13. Competitive Assessment

    13.1. Market Competition – a Dashboard View

    13.2. Market Structure, By Tier

14. Company Profiles

    14.1. AstraZeneca

        14.1.1. Company Overview

        14.1.2. Key Developments

        14.1.3. Segment Financials

        14.1.4. Product Portfolio

        14.1.5. Key Strategies

    14.2. Kowa Pharmaceuticals America, Inc.

        14.2.1. Company Overview

        14.2.2. Key Developments

        14.2.3. Segment Financials

        14.2.4. Product Portfolio

        14.2.5. Key Strategies

    14.3. Merck & Co.

        14.3.1. Company Overview

        14.3.2. Key Developments

        14.3.3. Segment Financials

        14.3.4. Product Portfolio

        14.3.5. Key Strategies

    14.4. Pfizer

        14.4.1. Company Overview

        14.4.2. Company Overview

        14.4.3. Key Developments

        14.4.4. Segment Financials

        14.4.5. Product Portfolio

        14.4.6. Key Strategies

    14.5. Sanofi

        14.5.1. Company Overview

        14.5.2. Key Developments

        14.5.3. Segment Financials

        14.5.4. Product Portfolio

        14.5.5. Key Strategies

    14.6. Amgen

        14.6.1. Company Overview

        14.6.2. Key Developments

        14.6.3. Segment Financials

        14.6.4. Product Portfolio

        14.6.5. Key Strategies

    14.7. Novelion Therapeutics

        14.7.1. Company Overview

        14.7.2. Key Developments

        14.7.3. Segment Financials

        14.7.4. Product Portfolio

        14.7.5. Key Strategies

    14.8. Mylan

        14.8.1. Company Overview

        14.8.2. Key Developments

        14.8.3. Segment Financials

        14.8.4. Product Portfolio

        14.8.5. Key Strategies

    14.9. Abbott Laboratories

        14.9.1. Company Overview

        14.9.2. Key Developments

        14.9.3. Segment Financials

        14.9.4. Product Portfolio

        14.9.5. Key Strategies

    14.10. Novartis AG

        14.10.1. Company Overview

        14.10.2. Key Developments

        14.10.3. Segment Financials

        14.10.4. Product Portfolio

        14.10.5. Key Strategies

15. Assumptions and Acronyms Used

16. Research Methodology



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 脂質異常症治療薬の世界市場2023年-2033年：予測・動向・分析・競争状況(Dyslipidemia Therapeutics Market By Type (Low-density Lipoproteins (LDL), Triglycerides), By Drug Class (Statins, Non-Statins, Combination Drugs), By Distribution Channel (Hospitals Pharmacies, Drug Stores, Retail Stores, Mail Order Pharmacies), and Region - Global Market Insights 2023 to 2033)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 大発作治療の世界市場2023年-2033年：予測・動向・分析・競争状況
  • 低電圧モーターの世界市場2023年-2033年：予測・動向・分析・競争状況
  • ペプチド感染症治療薬の世界市場2023年～2033年：予測・動向・分析・競争状況
  • ペプチドベース心臓血管治療薬の世界市場2023年-2033年：予測・動向・分析・競争状況
  • ペプチド治療薬（メタボリックシンドローム用）の世界市場2023年～2033年：予測・動向・分析・競争状況

    • ◆H&Iグローバルリサーチのお客様（例）◆